4974.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 06:39):

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...

Stats
Dzisiejszy wolumen	111 500
Średni wolumen	362 171
Kapitalizacja rynkowa	123.55B
EPS	¥0 ( 2024-02-14 )
Następna data zysków	( ¥14.90 ) 2024-05-10
Last Dividend	¥42.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	78.50
ATR14	¥0.475 (0.05%)

Wolumen Korelacja

Długi: 0.35 (neutral)

Krótki: -0.68 (moderate negative)

Signal:(78.911) Neutral

Takara Bio Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Takara Bio Inc. Korelacja - Waluta/Towar

0.32
( neutral )

0.78
( moderate )

0.28
( neutral )

0.29
( neutral )

0.48
( neutral )

-0.73
( moderate negative )

Takara Bio Inc. Finanse

Annual	2022
Przychody:	¥78.14B
Zysk brutto:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
Przychody:	¥78.14B
Zysk brutto:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
Przychody:	¥67.70B
Zysk brutto:	¥49.21B (72.69 %)
EPS:	¥164.84

FY	2021
Przychody:	¥46.09B
Zysk brutto:	¥31.87B (69.16 %)
EPS:	¥79.29

Financial Reports:

No articles found.

Takara Bio Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥42.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.16 - good (81.59%) | Divividend Growth Potential Score: 6.07 - Stable (21.43%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.000	2012-03-28
Last Dividend	¥42.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	13	--
Total Paid Out	¥114.10	--
Avg. Dividend % Per Year	0.00%	--
Score	2.76	--
Div. Sustainability Score	8.16
Div.Growth Potential Score	6.07
Div. Directional Score	7.12	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.76

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8182.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7564.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6768.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6104.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4820.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4028.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3245.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
2270.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9763.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
8842.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0330	1.500	9.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0128	1.200	9.57	10.00	[0 - 0.3]
returnOnEquityTTM	0.0141	1.500	-0.954	-1.431	[0.1 - 1]
payoutRatioTTM	3.21	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	7.45	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.46	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.25	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	61.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.553	1.000	4.11	4.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0309	1.000	-1.382	-1.382	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.387	0.800	-0.751	-0.601	[0.5 - 2]
Total Score				8.16

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	77.72	1.000	2.25	0	[1 - 100]
returnOnEquityTTM	0.0141	2.50	-0.613	-1.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.677	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	3.21	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	53.82	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.506	1.000	10.00	0	[0.1 - 0.5]
Total Score				6.07

Takara Bio Inc.

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Aktualne aktualizacje dla Takara Bio Inc. [4974.T]

Upcoming Earnings Alert

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for JPX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)